# A Trial Evaluating TG4050 in Ovarian Carcinoma.

Source: https://onco.cc/trials/nct03839524/  
OnCo record `nct03839524` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of TG4050 run by Transgene, completed.

## Summary

A Trial Evaluating TG4050 in Ovarian Carcinoma. is a phase 1 interventional study registered as NCT03839524 by Transgene, with 64 participants enrolled, started 2019-12-09. Conditions recorded: Ovarian Carcinoma, Fallopian Tube Cancer and Peritoneal Carcinoma. Interventions recorded: TG4050.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03839524
- Phase: 1
- Setting: A Phase I Trial Evaluating a Mutanome-directed Immunotherapy in Patients With High Grade Serous Carcinoma (HGSC) of the Ovary, Fallopian Tube or Peritoneum.
- Sponsor: Transgene
- Enrolled: 64

## Sources

- ClinicalTrials.gov NCT03839524: https://clinicaltrials.gov/study/NCT03839524

## Connected records

- cancers: [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [TG4050](https://onco.cc/drugs/tg4050/)
- companies: [Transgene](https://onco.cc/companies/transgene/)

---
JSON: https://onco.cc/api/v1/entities/nct03839524.json